About the Event
Date:On Demand
Location:Virtual
Credit:CME: 1.25
On Demand:Available
The ACR Convergence Replay 2024 webinar series includes recorded sessions from ACR Convergence followed by a live Q&A with the presenters to answer your questions and provide further insights.
This session is about the latest advancements and challenges in the management of ANCA-associated vasculitis (AAV). Although treatment guidelines have become available, many questions persist about their specific application to different clinical scenarios and patient population with ANCA-associated vasculitis (AAV). In addition, recent evidence has reopened the debate about low versus standard dose glucocorticoids. An ongoing controversy about the use of plasmapheresis persists despite the findings of the PEXIVAS study. The use of avacopan has opened an opportunity for glucocorticoid minimization and remaining indications for cyclophosphamide are important to discuss.
Target Audience
Rheumatologists, physicians, healthcare providers who care for patients with rheumatic diseases, and those interested or engaged in rheumatology research.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Review general and specific applications of the American College of Rheumatology/Vasculitis Foundation treatment guidelines for GPA and MPA
- Discuss recent data regarding use of low versus standard dose glucocorticoids in AAV
- Discuss and review applications for avacopan in AAV
- Discuss and review current indications for plasmapheresis in AAV
Note: On-demand access will be available for registered attendees. On-demand access will also be available for purchase to non-registrants within 30 days of the live program.
Program Schedule & Syllabi
Registered attendees can access the syllabi during the meeting and until 11:59 PM ET on December 31, 2025. To access syllabi, login and go to My Learning.
Registration Fees
Registration is closed.
Acknowledgement of Commercial Support
No commercial support was provided for this activity.
This activity is not eligible for MOC.
CME
ACCME Accreditation Statement
The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
See the ACR’s CME Mission Statement. For more information, download the AMA PRA Booklet.
AMA Designation Statement
The American College of Rheumatology designates this Virtual Activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME credit must be claimed by December 31, 2025, at 11:59 PM ET.
Instructions to Claim CME Credit
Credit claiming is available after the activity starts.
The deadline to claim CME credit for ACR Convergence Replay Webinar: Controversies in the Treatment of ANCA-Associated Vasculitis is December 31, 2025.
- Log in to the My Credit page.
- Locate ACR Convergence Replay Webinar: Controversies in the Treatment of ANCA-Associated Vasculitis and click Claim Credit. Enter the amount of credit commensurate with your participation. (To view or update your credit, select View Credit.)
Certificates
After claiming credit, you can access and print certificates in the ACR Learning Center on the My Learning page.
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
- Advisor or review panel member
- Consultant
- Employee
- Officer or Board Member
- Grant/research support
- Speaker/honoraria includes speakers bureau, symposia, and expert witness
- Independent contractor
- Executive role and/or ownership interest
- Royalties and/or patient beneficiary
- Intellectual property/patents
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Private investigator
- Expert witness
- Equity interest
- Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.
The ACR Convergence 2024 Replay Webinar: Controversies in the Treatment of ANCA-Associated Vasculitis took place on April 15, 2025.
Target Audience
Rheumatologists, physicians, healthcare providers who care for patients with rheumatic diseases, and those interested or engaged in rheumatology research.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Review general and specific applications of the American College of Rheumatology/Vasculitis Foundation treatment guidelines for GPA and MPA
- Discuss recent data regarding use of low versus standard dose glucocorticoids in AAV
- Discuss and review applications for avacopan in AAV
- Discuss and review current indications for plasmapheresis in AAV
Program Schedule & Syllabi
Registered attendees can access the syllabi during the meeting and until 11:59 PM ET on December 31, 2025. To access syllabi, login and go to My Learning.
CE & MOC Information
This activity is not eligible for MOC.
CME
ACCME Accreditation Statement
The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
See the ACR’s CME Mission Statement. For more information, download the AMA PRA Booklet.
AMA Designation Statement
The American College of Rheumatology designates this Virtual Activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME credit must be claimed by December 31, 2025, at 11:59 PM ET.
Instructions to Claim CME Credit
Credit claiming is available after the activity starts.
The deadline to claim CME credit for ACR Convergence Replay Webinar: Controversies in the Treatment of ANCA-Associated Vasculitis is December 31, 2025.
- Log in to the My Credit page.
- Locate ACR Convergence Replay Webinar: Controversies in the Treatment of ANCA-Associated Vasculitis and click Claim Credit. Enter the amount of credit commensurate with your participation. (To view or update your credit, select View Credit.)
Certificates
After claiming credit, you can access and print certificates in the ACR Learning Center on the My Learning page.
Financial Relationships Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.
Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:
- Advisor or review panel member
- Consultant
- Employee
- Officer or Board Member
- Grant/research support
- Speaker/honoraria includes speakers bureau, symposia, and expert witness
- Independent contractor
- Executive role and/or ownership interest
- Royalties and/or patient beneficiary
- Intellectual property/patents
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Private investigator
- Expert witness
- Equity interest
- Other: specify details
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.
Acknowledgement of Commercial Support
No commercial support was provided for this activity.